Phreesia (PHR) to Release Earnings on Wednesday

Phreesia (NYSE:PHR) is expected to be posting its quarterly earnings results after the market closes on Wednesday, March 12th. Analysts expect Phreesia to post earnings of ($0.19) per share and revenue of $108.93 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same period in the previous year, the business posted ($0.58) earnings per share. The business’s revenue was up 16.6% compared to the same quarter last year. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Stock Performance

NYSE PHR opened at $23.69 on Monday. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -16.12 and a beta of 1.03. The business’s 50 day moving average is $27.45 and its two-hundred day moving average is $24.02. Phreesia has a 12-month low of $17.07 and a 12-month high of $30.53. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PHR. JMP Securities reissued a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Robert W. Baird cut their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and upped their price target for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. Citigroup upped their price target on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Finally, Truist Financial upped their price target on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Thirteen analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $31.15.

Insider Buying and Selling at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 3,495 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $24.88, for a total value of $86,955.60. Following the transaction, the general counsel now directly owns 116,296 shares of the company’s stock, valued at $2,893,444.48. This represents a 2.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP David Linetsky sold 11,853 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $24.85, for a total value of $294,547.05. Following the completion of the transaction, the senior vice president now directly owns 188,354 shares in the company, valued at approximately $4,680,596.90. The trade was a 5.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 195,740 shares of company stock valued at $5,441,409 over the last three months. 5.80% of the stock is owned by company insiders.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.